Transillumination images of objects hidden in normal and cancerous human breast tissues and bovine, porcine, and gallinaceous (chicken) tissues as well as model-random-scattering media were recorded with 1250-nm light from a chromium-doped forsterite laser. A Fourier space gate and a polarization gate were used to sort out image-bearing photons and discriminate against multiply scattered image-blurring photons. Better contrast, higher spatial resolution, and deeper penetration of samples were achieved for imaging with 1250-nm light than those obtained at shorter wavelengths, such as 1064 nm from a neodymium-doped yttrium aluminum garnet (YAG) laser. Better contrast and higher resolution were also obtained when the object was imaged through normal human breast tissue than through cancerous breast tissue. Images with marked distinction between fatty and fibrous human breast tissues were obtained when the Cr:forsterite laser was tuned to 1225 nm, a wavelength that resonates with an optical absorption band of breast fat tissues. Imaging with linearly polarized light revealed that the image quality depends significantly on the orientation of the polarization of the incident light with respect to the fibers in the bovine tissue.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1364/ao.37.005327 | DOI Listing |
N Engl J Med
January 2025
From the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation (C.E.G., E.P.M., N.W., P.R., I.L.W., A.M.B.) and University of Pittsburgh School of Medicine-UPMC Hillman Cancer Center (C.E.G., N.W., P.R., A.M.B.) - both in Pittsburgh; AGO-B and Helios Klinikum Berlin-Buch, Berlin (M.U.), the National Center for Tumor Diseases, Heidelberg University Hospital, and German Cancer Research Center, Heidelberg (A.S.), Evangelische Kliniken Gelsenkirchen, Gelsenkirchen (H.H.F.), Arbeitsgemeinschaft Gynäkologische Onkologie-Breast and Sana Klinikum Offenbach, Offenbach (C.J.), the Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), German Breast Group, Neu-Isenburg (P.W., S.L.), and the Center for Hematology and Oncology Bethanien, Goethe University, Frankfurt (S.L.) - all in Germany; National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-S.H.); Instituto do Câncer do Estado de São Paulo, São Paulo (M.S.M.); Orlando Health Cancer Institute, Orlando, FL (E.P.M.); Hospital Universitario La Paz-Instituto de Investigación del Hospital Universitario La Paz, Madrid (A.R.); L'Institut du Cancer de Montpellier-Val d'Aurelle, Montpellier (V.D.), Institut Bergonié, INSERM Unité 1312, and Université de Bordeaux UFR Sciences Médicales, Bordeaux (H.R.B.) - all in France; Providence Cancer Institute, Portland, OR (A.K.C.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and Oncology 2, Istituto Oncologico Veneto IRCCS, Padua (V.G.), and the Cancer Center Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (E.R.C.) - all in Italy; Stanford University School of Medicine, Stanford, CA (I.L.W.); the National Cancer Institute, Mexico City (C.A.-S.); Yale University School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, CT (M.P.D.); the All-Ireland Cooperative Oncology Research Group (J.P.C.), and the Oncology Unit, Cancer Clinical Trials and Research Unit, Beaumont RCSI Cancer Centre, and Cancer Trials Ireland (B.T.H.) - all in Dublin; Fudan University Shanghai Cancer Center, Shanghai, China (Z.S.); Institute for Oncology and Radiology of Serbia, Belgrade (L.S.); Grupo Médico Ángeles, Guatemala City, Guatemala (H.C.-S.); Roche Products, Welwyn Garden City, United Kingdom (A.K., A.S.); and F. Hoffmann-La Roche, Basel, Switzerland (C.L., T.B., B.N., E.R.).
Background: Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with trastuzumab alone.
Methods: We randomly assigned patients with HER2-positive early breast cancer with residual invasive disease in the breast or axilla after neoadjuvant systemic treatment with taxane-based chemotherapy and trastuzumab to receive T-DM1 or trastuzumab for 14 cycles.
Rev Gaucha Enferm
January 2025
Universidade Federal do Pará. Belém. Pará. Brasil.
Objective: to describe the perception of health professionals and managers in the prison system regarding the continuity of breastfeeding care for lactating women deprived of liberty.
Method: descriptive-exploratory research, qualitative approach, developed in a prison unit in Rio de Janeiro from December 2022 to January 2023. Interviewees: five health professionals and two managers.
Rev Gaucha Enferm
January 2025
Universidade Federal de Pernambuco (UFPE), Recife, Pernambuco, Brasil.
Objective: To analyze the concept of sexual dysfunction in postpartum women and identify their essential attributes, antecedents, and effects.
Method: Concept analysis based on a framework by Walker and Avant, elaborated in eight stages, which were: concept selection; identification of the use of the concept; determination of essential attributes; construction of the model case; additional case; identification of antecedents and effects; and definition of empirical references. Furthermore, an integrative review was carried out simultaneously, with a view to supporting the analysis of the concept.
Sci Adv
January 2025
Istituto per l'Endocrinologia e l'Oncologia Sperimentale "G. Salvatore", IEOS-CNR, Napoli, Italy.
CD4FOXP3 regulatory T cells (T) suppress immune responses to tumors, and their accumulation in the tumor microenvironment (TME) correlates with poor clinical outcome in several cancers, including breast cancer (BC). However, the properties of intratumoral T remain largely unknown. Here, we found that a functionally distinct subpopulation of T, expressing the FOXP3 Exon2 splicing variants, is prominent in patients with hormone receptor-positive BC with poor prognosis.
View Article and Find Full Text PDFSci Adv
January 2025
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Small extracellular vesicles (sEVs) are nanosized vesicles. Death receptor 5 (DR5) mediates extrinsic apoptosis. We engineer DR5 agonistic single-chain variable fragment (scFv) expression on the surface of sEVs derived from natural killer cells.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!